INTRODUCTION
Dupilumab is a selectively immunosuppressive biologic therapy that treats chronic moderate-tosevere atopic dermatitis through inhibiting signaling transmission of interleukins (IL) 4 and 13. It is often prescribed when patients do not respond to or cannot tolerate conventional topical or systemic therapies. Most commonly reported side effects include injection site reactions, eye and eyelid inflammation, and nasopharyngitis. 1, 2 This case report highlights a patient who experienced druginduced alopecia at 18 weeks on dupilumab.
CASE REPORT
A 27 year-old Hispanic man was started on dupilumab after not responding to several topical steroids, tacrolimus ointment, oral steroids, and oral antihistamines. His baseline body surface area affected was 8% with an Investigator's Static Global Assessment of 3. He noted immediate improvements in his condition and quality of life after a few doses of dupilumab. The patient had an affected body surface area of 6% and Investigator's Static Global Assessment of 1 at 18 weeks on dupilumab when he noted increased hair loss on the scalp. The medication was otherwise well tolerated by the patient, and he reported no other significant side effects. Hair loss did not subside with daily clobetasol 0.05% foam and 3-times weekly ketoconazole 2% shampoo use. Diffuse pink background erythema with ill-defined areas of nonscarring alopecia on the crown and temporal scalp were noted on examination (Fig 1) Punch biopsy results showed alopecia areata-like hair miniaturization with peribulbar chronic inflammation and severe sebaceous gland atrophy (Figs 2 and 3).
We speculated that if dupilumab was stopped and normal hair regrowth resumed, circumstantial evidence would point to a drug-induced alopecia rather than true alopecia areata. The patient discontinued dupilumab, continued topical triamcinolone acetonide 0.1% ointment to the scalp alternating weekly with tacrolimus 0.1% ointment, and received 1.3 mL of 10 mg/mL intralesional triamcinolone acetonide to approximately 30 sites. No remaining areas of alopecia, scale, or erythema were noted on examination 8 weeks later (Fig 4) . Our patient's recovery was faster than anticipated given the extent of hair loss that he had compared with the minimal amount of intralesional steroid treatments administered.
DISCUSSION
The underlying autoimmune processes of alopecia areata are not easily illuminated, so the relationship between use of dupilumab and development of alopecia in this patient is strongly correlated but cannot be definitely declared as causative. Research has found that both atopic dermatitis and alopecia areata are involved in type 2 T-helper (Th) cytokine regulation. 3, 4 Specifically, the expression of IL-4 and IL-13 has been positively correlated with the expression of sebaceous gland signatures. 5 The mechanism of dupilumab in interrupting IL-4 and IL-13 processes in Th2-mediated inflammation and sebaceous gland development could therefore provoke an imbalance in interleukin milieu that contributes to sebaceous gland atrophy and nonscarring alopecia. Sebaceous gland atrophy is a feature of other drug-induced alopecia areataelike reactions and other inflammatory skin conditions such as psoriasis, but it is not seen in alopecia areata. 6 More investigation is needed to establish how these pathologic conditions may further overlap; for example, the Th17/IL-23 pathway is one of many currently being investigated for its contribution to both atopic dermatitis and alopecia areata. 4, 7, 8 One other reported case describes similar hair loss with dupilumab, and our case further lends support to this possible side effect. 9 Conversely, one recently published case report describes effective treatment of both atopic dermatitis and pre-existing alopecia areata while on dupilumab. 10 This difference in clinical outcomes, in conjunction with the observed difference in histologic features of drug-induced alopecia versus alopecia areata, suggests a phenotype for dupilumab-induced alopecia distinct from a true alopecia areata. Scalp biopsy of patients clinically suspicious for drug-induced alopecia is recommended to rule out this pathophysiology and guide treatment. It is important to make prescribers aware of newly discovered phase IV, postmarketing associations when they consider dupilumab with their patients in a clinical setting. In this image, 2 anagen phase and 1 telogen phase hairs are seen, but sebaceous glands are severely atrophic and can barely be recognized as sebaceous structures. Mild, chronic perivascular inflammation can also be appreciated at this level. 
